A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment
NCT02805699 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2017-08-30
Summary
The purpose of this study is to confirm the efficacy and safety of BaofeiKang Granule in the treatment of Combined Pulmonary Fibrosis and Emphysema patients.
Conditions
- Combined Pulmonary Fibrosis and Emphysema
Interventions
- DRUG
-
Baofeikang Granule
To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
- DRUG
-
On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
Sponsors & Collaborators
-
Beijing Municipal Science & Technology Commission
lead OTHER
Principal Investigators
-
hongsheng cui, Ph.D，Professor · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
weibo Bi, Master · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
jianjun Wu, Master · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
ruifeng Jin, Master · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
chang'an Li, Master · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
minmin Shan, Master · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
qiuyi Chen, Bachelor · The Third Affiliated Hospital of Beijing University of Chinese Medicine
-
shengtao li, Bachelor · The Third Affiliated Hospital of Beijing University of Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 45 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-06-30
- Primary Completion
- 2019-06-30
- Completion
- 2019-09-30
Countries
- China
Study Locations
More Related Trials
-
Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome
NCT06431555 ·Status: RECRUITING
-
Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage
NCT06326658 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule
NCT06673121 ·Status: RECRUITING
-
Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD
NCT04544722 ·Status: UNKNOWN ·Phase: NA
-
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT02058602 ·Status: COMPLETED ·Phase: PHASE1
-
Air Pollution and Health of COPD Patients
NCT05076630 ·Status: COMPLETED
-
The Effect of Theophylline in the Treatment of Bronchiectasis
NCT01684683 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
NCT07141810 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Small Bioactive Molecules in Early COPD Diseases
NCT04950023 ·Status: UNKNOWN
-
The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China
NCT03044847 ·Status: ENROLLING_BY_INVITATION
-
Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis (Clinical and Biochemical Study)
NCT04474717 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study of Optimized CT-guided Pulmonary Nodule Microcoil Localization Technique
NCT03649906 ·Status: COMPLETED ·Phase: NA
-
Disease-syndrome Characteristics of IPF
NCT07178392 ·Status: NOT_YET_RECRUITING
-
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia
NCT03473119 ·Status: UNKNOWN
-
Exhaled Breath Condensate Biomarkers and Cough in IPF
NCT02630940 ·Status: COMPLETED
-
Bufei Recipe Reduces the Incidence Rate of COPD
NCT06375824 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
NCT00001759 ·Status: COMPLETED
-
Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis
NCT06715956 ·Status: NOT_YET_RECRUITING
-
Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study
NCT02564731 ·Status: UNKNOWN
-
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
NCT05032898 ·Status: UNKNOWN
-
Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT03092648 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease
NCT00147095 ·Status: COMPLETED
-
Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD
NCT06275230 ·Status: RECRUITING
-
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
NCT06987214 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575 ·Status: NOT_YET_RECRUITING